Ninerafaxstat, an investigational drug being studied by Imbria Pharmaceuticals, may be the first drug specifically for non-obstructive hypertrophic cardiomyopathy.
The results of the Improve-HCM Phase 2 study were published last week in the Journal of the American College of Cardiology (ACC) and simultaneously presented at last week’s meeting of the ACC in Atlanta.
The Improve study found that the drug is safe, and that patients demonstrated improvements to both exercise performance and symptoms.
The findings support advancement to a Phase 3 study to focus on efficacy of the drug.
You can read more about the IMPROVE trial here.
HCM Beat 